ATX 0.00% 15.5¢ amplia therapeutics limited

Competitor?, page-2

  1. 4,696 Posts.
    lightbulb Created with Sketch. 72
    Not a competitor imo

    From the 25th Sept dated BioShares

    "Innate is conducting a 90 patient, placebo-controlled trial in secondary progressive multiple sclerosis (SPMS).

    There is currently no approved treatment for SPMS, which is a rapidly deteriorating form of the disease which follows the relapsing-remitting phase that is well serviced by existing therapies."
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.